Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Olopatadine 0.1% (Patanol) and olopatadine 0.2% (Pataday) ophthalmic solutions are topical ocular anti-allergic agents with antihistaminic and mast cell stabilizing properties. The efficacy of two doses of olopatadine 0.1% was compared to one dose of olopatadine 0.2% in the prevention of ocular itching associated with allergic conjunctivitis over 24 hours. This double-masked conjunctival allergen challenge (CAC) study found no significant difference in the mean itching scores between two drops of olopatadine 0.1% and one drop of olopatadine 0.2%. Both showed significant activity at the 24-hour time point and were statistically superior to placebo. No adverse events occurred while on drug therapy.
Abelson
Mark B
MB
Harvard Medical School, Schepens Eye Research Institute, Department of Ophthalmology, Boston, Massachusetts, USA.
Spangler
Dennis L
DL
Epstein
Arthur B
AB
Mah
Francis S
FS
Crampton
H Jerome
HJ
D000328:Adult; D000485:Allergens / Q000009:adverse effects; D003228:Conjunctiva / Q000187:drug effects; D003233:Conjunctivitis, Allergic / Q000139:chemically induced / Q000188:drug therapy*; D003990:Dibenzoxepins / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D000069605:Olopatadine Hydrochloride; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D011537:Pruritus / Q000188:drug therapy*; D012882:Skin Tests; D016896:Treatment Outcome
D000485:Allergens; D003990:Dibenzoxepins; D039563:Histamine H1 Antagonists, Non-Sedating; D009883:Ophthalmic Solutions; D000069605:Olopatadine Hydrochloride